Welcome to our dedicated page for Elite Pharmaceuticals SEC filings (Ticker: ELTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elite Pharmaceuticals, Inc. filings document a Nevada specialty pharmaceutical issuer with common stock trading under ELTP on the OTCQB. The company's SEC reports include Form 8-K disclosures for quarterly results, Regulation FD updates, press-release exhibits, and amendments to current reports.
Recent filings describe financial-result announcements linked to Form 10-Q reporting, FDA approval and launch disclosures for generic drug products, and product marketing under the Elite Laboratories, Inc. label. The filing record also identifies the company's common stock class and provides formal notice of material events related to its niche generic pharmaceutical business.
Elite Pharmaceuticals, Inc. has commercially launched its generic methadone hydrochloride 5 mg and 10 mg tablets in the United States under the Elite Laboratories, Inc. label. These tablets are used for severe, persistent pain and for detoxification and maintenance treatment of opioid addiction alongside medical and social support services.
Based on IQVIA data, combined brand and generic methadone tablet products generated approximately $22 million in annual retail sales in 2025, indicating a modest but established market. Elite develops and distributes niche generic, oral controlled-release drugs from its cGMP and DEA-registered facility in Northvale, New Jersey.
Elite Pharmaceuticals, Inc. reported very strong results for the third quarter of fiscal 2026, the three months ended December 31, 2025. Consolidated revenues were $31.6 million, up $17.2 million or about 120% from the same period a year earlier. Income from operations reached $9.0 million, an increase of $7.9 million, roughly 721% higher than the prior-year quarter, driven mainly by sales of Elite’s lisdexamfetamine and naltrexone products and strong growth in Elite label products. Net income for the quarter was $18.6 million. Management will discuss these results and recent business developments on a conference call scheduled for February 18, 2026, at 11:30 EST.
Elite Pharmaceuticals reported sharply improved results for the quarter and nine months ended December 31, 2025. Total revenue reached $31.6 million this quarter and $108.1 million year‑to‑date, up from $14.4 million and $52.0 million a year earlier, driven mainly by higher manufacturing fees.
Net income was $18.6 million for the quarter versus a $10.9 million loss last year, and $26.4 million year‑to‑date versus a $21.3 million loss. Results include a sizeable non‑cash gain from changes in warrant fair value. Basic EPS was $0.02 for both the quarter and nine months.
Cash and restricted cash increased to $21.6 million from $8.7 million year‑earlier, helped by $14.6 million of operating cash flow and repayment of $4.0 million and $1.0 million of related‑party loans. One customer represented 64% of revenue and 70% of receivables, and the company continues ANDA‑focused operations while pursuing new generic launches and managing ongoing patent litigation over a proposed generic OxyContin.
Elite Pharmaceuticals, Inc. filed a current report announcing it will release financial results for the third quarter of fiscal year 2026, ended December 31, 2025, on February 17, 2026. Management will host a conference call on February 18, 2026 at 11:30 EST to discuss the results and provide a corporate update.
Investors can join the call by dialing 1-800-346-7359 (domestic) or 1-973-528-0008 (international) using conference number 98840, and are invited to email general and financial questions in advance to dianne@elitepharma.com by the specified deadlines.
Elite Pharmaceuticals executive Douglas Plassche reported an option exercise. On 01/09/2026, the EVP of Operations exercised stock options covering 2,500,000 shares of Elite Pharmaceuticals common stock at an exercise price of $0.03 per share, converting them into 2,500,000 shares of common stock.
The stock options were fully vested and exercisable as of the transaction date. Following this transaction, Plassche directly beneficially owns 6,000,000 shares of Elite Pharmaceuticals common stock and holds no remaining derivative securities from this reported option grant.
Elite Pharmaceuticals (ELTP) filed an 8-K noting it filed its Form 10‑Q for the quarter ended September 30, 2025 and issued a press release with those results. The company will host a conference call on November 17, 2025 at 11:30 AM EST to provide a business update and answer pre-submitted stockholder questions.
Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international), conference number 98840. Financial questions may be emailed to dianne@elitepharma.com by 7:00 PM EST on November 14, 2025. An audio replay will be available at https://elite.irpass.com/events_presentations.
Elite Pharmaceuticals (ELTP) reported a strong Q2 FY2026. Total revenue reached $36,321,704 for the quarter, up from $18,880,345 a year ago, driven by manufacturing fees. Gross profit was $14,073,033. Income from operations rose to $8,213,746. A $7,519,649 favorable change in warrant fair value lifted other income, resulting in net income attributable to common shareholders of $13,702,407, or $0.01 per basic and diluted share.
For the six months, revenue was $76,532,801 with income from operations of $29,913,453 and net income of $7,817,692 after $7,308,441 of income tax expense. Cash was $26,617,346 as of September 30, 2025, up from $11,315,385, aided by $19,880,115 net cash from operating activities; related party loans of $4,000,000 were repaid. Accounts receivable rose to $40,871,924, and warrant liabilities were $39,789,081. Shares outstanding were 1,074,496,422 as of November 14, 2025. Subsequent to quarter end, the FDA approved Elite’s ANDA for generic Requip XL (Ropinirole ER tablets) under the Elite Laboratories label.
Elite Pharmaceuticals (ELTP) filed an 8-K/A to amend its earlier report, solely to correct the date of its conference call. The company will host the call to discuss financial results for the second quarter of fiscal 2026, covering the period ended September 30, 2025.
The conference call is scheduled for Monday, November 17, 2025, at 11:30 AM EST. Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international), conference number 98840. General questions may be emailed to dianne@elitepharma.com by 5:00 PM EST on November 13, 2025, and financial questions by 7:00 PM EST on November 14, 2025. The information is being furnished under Items 2.02, 7.01 and 9.01 and is not deemed filed under the Exchange Act.
Elite Pharmaceuticals (ELTP) announced FDA approval for its generic version of Requip XL (Ropinirole Extended-Release Tablets USP). The approval covers 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths used to treat symptoms of Parkinson’s disease. The product will be marketed and sold under the Elite Laboratories, Inc. label.
The company furnished a press release with these details as Exhibit 99.1. Information in this item and the press release is provided under Regulation FD and is not deemed filed under the Exchange Act.
Elite Pharmaceuticals (ELTP) announced it will host a conference call to discuss its second quarter fiscal 2026 results for the period ended September 30, 2025. The call is scheduled for November 14, 2025, at 11:30 AM EST.
Participants can dial 1-800-346-7359 (domestic) or 1-973-528-0008 (international) and use conference number 98840. Questions may be emailed to dianne@elitepharma.com; general questions are due by 5:00 PM EST on November 13, 2025, and financial questions by 7:00 PM EST on November 14, 2025.